Annual report

VALBIOTIS publishes its 2018 annual report and announces its results.

Read the document

VALEDIA®

VALBIOTIS obtains the European patent for VALEDIA®.

Read the press release

VALEDIA®

A major scientific innovation for people with prediabetes.

Prediabetes

VALBIOTIS publishes the first prediabetes market data.

Read the press release
S c r o l l

Products

.01

Pipeline

4 products in clinical development

Learn more

.02

VALEDIA® – Prediabetes

Prediabetes
• Reduction of the risk of type 2 diabetes
• Phase IIa clinical study ongoing

Learn more

.03

LpD64

Overweight and /or obesity
• Modulation of intestinal microbiota
• Clinical Phase I/II positive

Learn more

.04

VAL-070

Mild to moderate hypercholesterolemia
• Reduction of blood LDL-cholesterol
• Clinical Phase I/II positive

Learn more

.05

VALEDIA® – Non alcoholic fatty liver

Non-alcoholic fatty liver (NAFL)
• Reduction of NAFL, risk factor for NASH
• Clinical Phase I/II positive

Learn more

Key figures

Patent families filed

4
All exploitation rights obtained

Employees

> 35
75% in R&D

Listed on the Stock Exchange

2017
Euronext Growth

Our last posts

17.04.2019

Small Cap Event Invest Securities

En savoir plus
10.04.2019

MidCap Portzamparc Conference

En savoir plus
04.04.2019

Market Solutions Forum

En savoir plus
26.03.2019

Biotech Agora

En savoir plus
Voir tous

VALBIOTIS© listed on the Stock Exchange

Investors

Follow us!

See more